# Bellicum Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bellicum-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Houston, US
- Website: www.bellicum.com
- Total disclosed funding: $89M
- Latest round: Series C (Aug 27, 2014)
- Investors on record: 11

## About

Bellicum Pharmaceuticals, Inc. is a biotechnology firm focused on developing advanced cell therapies for cancer treatment, leveraging its proprietary technology to enhance the efficacy of immunotherapy.Founded in 2003 and headquartered in Houston, US, Bellicum Pharmaceuticals, Inc. specializes in developing cell therapies that enhance immune response to cancer. The company has successfully raised a total of USD 35.00 mn, with the latest funding being a Private Placement/Follow on in March 2017, amounting to USD 35.00 mn. The founder, Kevin Slawin, has a background in medical technology and entrepreneurship, contributing to the firm’s innovative approach. The company has engaged in a total of 18 deals to date, demonstrating active involvement in funding and development.Bellicum Pharmaceuticals focuses on cell therapy solutions aimed at improving cancer treatment through innovative technologies. Their primary offerings include engineered T cell therapies that utilize a proprietary platform designed to enhance the safety and effectiveness of such treatments, specifically addressing challenges encountered in oncology. These products are targeted at healthcare providers and research institutions, with a commitment to advancing patient care in the oncology sector.In 2022, Bellicum Pharmaceuticals recorded a revenue of USD 1.50 mn. The company operates primarily on a subscription-based model for its therapeutic products, while also entering strategic partnerships to provide integrated healthcare solutions. The revenue structure is complemented by additional services such as training and support, aimed at optimizing the use of their therapies by medical professionals.Bellicum Pharmaceuticals plans to expand its portfolio by launching new cell therapy products designed to address various cancer types, with expected releases aimed for late 2023. Additionally, the company intends to penetrate emerging markets in Asia and Europe, targeting a broader audience by 2025. The funds raised in previous rounds will be allocated towards research and development of these new therapies and enhancing market presence, allowing the company to capitalize on opportunities in the evolving landscape of cancer treatment.

## Funding rounds

- Series C, Aug 27, 2014, $55M — AJU IB Investment, Jennison Associates, Redmile Group, Remeditex Ventures, VenBio, AVG Ventures, RA Capital Management, Sabby Capital, Ridgeback Capital Management, Perceptive Advisors
- Series B, Oct 16, 2013, $15M — Remeditex Ventures, AVG Ventures
- Series B, Mar 8, 2012, $20M — Active Venture Partners, Remeditex Ventures

## Investors

- Active Venture Partners (https://capitalatlas.ai/funds/active-venture-partners) — Series B
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series B, Series C
- AVG Ventures — Series B, Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C
- Jennison Associates — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- VenBio (https://capitalatlas.ai/funds/venbio) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series C
- Ridgeback Capital Management — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C